Trump Invested More in Drugmakers That Benefited From Medicare Exemptions, Dems Say
(MedPage Today) -- Investments in pharmaceutical companies made on behalf of President Donald Trump increased significantly after he returned to the White House last year, with his portfolio adding millions of dollars in stock in firms that benefited...
A recent report by congressional Democrats reveals that President Donald Trump's pharmaceutical stock holdings grew substantially after he returned to the White House. In 2025, his portfolio added millions of dollars in shares of companies that benefited from Medicare exemptions, which the Republican-backed tax and spending law introduced in 2025.
The report found Trump's stock holdings grew from $1.7 million in 2024 to $56.2 million by the end of 2025. This increase included up to $39.1 million worth of stock in companies that enjoyed exemptions from Medicare's drug price negotiation program. The exemptions were part of the 2025 tax and spending law. The White House denied any ethics issues and accused Democrats of attempting to fabricate conflicts of interest.
Recent polling shows most Americans believe Trump is profiting from his presidency in unethical or illegal ways.
Written by urgent.news from PBS NewsHour's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
